FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

Under 16.19.6.24 NMAC, no nonresident pharmacy may ship, mail or deliver prescription drugs to a patient in New Mexico unless the Board of Pharmacy licenses it. Each out-of-state location needs its own license. Applicants must provide: their resident-state license; their most recent resident-state inspection report; a policy and procedure manual; toll-free telephone service for New Mexico patients (at least six days a week, 40 hours); and a New Mexico agent for service of process. They must also report annually on their officers and the pharmacists who dispense to New Mexico patients. A pharmacy shipping compounded sterile preparations must submit a sterile-compounding inspection report from the past 12 months, done by its resident-state board, a party that board recognizes, or a party the New Mexico board recognizes, showing it meets USP chapters numbered below 1000. The Board runs separate 'Non Resident Pharmacy' and 'Non Resident Sterile Pharmacy' applications. The rule does not require a New Mexico-licensed PIC.

16.19.6.24 was last amended 10/10/2023 according to the SRCA history note. Shipping controlled substances also needs DEA registration and a New Mexico controlled-substance registration (16.19.20 NMAC). The statute (NMSA 1978 §61-11-14) was not fetched; the rule rests on NMSA §61-11-6(A)(6). Stale flag: the underlying rule text was last amended before 2024-09-23 (as_of 2023-10-10), so it is possibly stale; no later amendment was found on the official host checked on 2026-09-23.

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

16.19.30 NMAC defines compounding as preparing a drug in response to a practitioner's prescription within a practitioner-patient-pharmacist relationship, or preparing limited quantities in anticipation of prescriptions based on a history of valid prescriptions. The only express 'office use preparations' allowance is for veterinary drugs used by veterinarians (16.19.30.9(A)(4)). Even there, the rule refers to outsourcing facilities as the preferred source for controlled-substance office stock. New Mexico licenses 503B outsourcing facilities, including nonresident ones, under 16.19.37 NMAC, and that is the route the rules provide for non-patient-specific human compounded drugs. This matches FDA's view that 503A compounding must be patient-specific.

The rules do not expressly ban human office-use compounding; the 'no' is based on how compounding is defined (prescription-based or anticipatory) and on office use being allowed only for veterinary drugs. 16.19.36 NMAC (sterile) has no office-use provision. The NM Pharmacy Act definitions (NMSA §61-11-2) were not fetched. Confirm with the NM Board of Pharmacy (505-222-9830). Stale flag: the underlying rule text was last amended before 2024-09-23 (as_of 2024-08-13), so it is possibly stale; no later amendment was found on the official host checked on 2026-09-23.

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

Under 16.19.37.8 NMAC, any nonresident outsourcing facility that distributes, or causes to be distributed, compounded sterile drugs into New Mexico must be FDA-registered under section 503B and licensed as a nonresident outsourcing facility. Initial and renewal licenses require: proof of FDA registration; proof of a resident-state license or registration if that state requires one; and an inspection report from the past 12 months by the resident-state agency, an entity it approves, or FDA, with any deficiencies corrected. Facilities must meet federal CGMP (21 CFR 211), DEA and USP requirements, and operate under a pharmacist-in-charge. Controlled substances also need DEA and New Mexico controlled-substance registration. A facility licensed both as an outsourcing facility and as a pharmacy or nonresident pharmacy is called a 'dual purpose facility'.

The 16.19.37 NMAC text on SRCA carries only its 12/13/2015 adoption history. The rule is about 10 years old (possibly stale), but the Board's July 2026 application manual confirms the Non Resident Outsourcing Facility license is current. Licenses renew every two years.

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. FDA lists only Colorado, Kentucky and New Hampshire as signatories; New Mexico is not among them. For a non-signing state, FD&C Act §503A(b)(3)(B)(ii) caps a 503A pharmacy's out-of-state distribution of compounded drugs at 5% of its total prescription orders. FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

16.19.20.8 NMAC lists practitioners who must register with the Board of Pharmacy - physicians, PAs, certified nurse practitioners, clinical nurse specialists, CNMs, CRNAs and others licensed to prescribe and administer controlled substances - and requires them to register with the NM PMP in conjunction with the CS registration. The CS registration fee is $180 every three years under 16.19.12 NMAC (the first period is prorated at $5 per month, per the Board's application form, rev. 2/2023), and the expiration month is set by the first letter of the last name. Under 16.19.20.13 NMAC a separate registration is required for each principal place of business or professional practice where drugs are dispensed or distributed, but not for a physician's office where controlled substances are only prescribed and not administered or dispensed. The Board's instructions describe obtaining the NM CS registration and the DEA registration before PMP enrollment.

Source older than 2 years - possibly stale: 16.19.20 NMAC was last amended 10/10/2023 and the fee rule 12/15/2020. The statute (NMSA 30-31-12) could not be opened (Justia blocked automated access), so the rule is cited instead. 16.19.20.8(I) lets an intern/resident/staff practitioner employed by a Board-licensed hospital or clinic work under the facility's registration.

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

Medical Board rule 16.10.14.8 NMAC requires MDs and PAs to review a 12-month PMP report before prescribing or dispensing a Schedule II-V controlled substance for the first time for more than four days (or after a 30-day gap) and at least every three months during continuous use; it exempts supplies of four days or less, nursing facility and hospice patients, and prescribing, dispensing or administering testosterone, pregabalin, lacosamide, ezogabine or stimulants for children under 14. The Board of Nursing rule for advanced practice nurses (16.12.9.9 NMAC) and the Board of Osteopathic Medicine rule (16.17.4.10 NMAC) contain the same Schedule II-V triggers but exempt only 4-day-or-less supplies, nursing facility patients and hospice patients, so testosterone is covered for APRNs and osteopathic physicians/PAs. The rules cover practitioners who dispense as well as prescribe.

Medical Board section 16.10.14.8 last amended 11/30/2016 and osteopathic rule adopted 6/11/2018 (both older than 2 years - possibly stale, but they are the versions currently posted by the NM State Records Center). The osteopathic board rule is still posted; whether New Mexico has since merged osteopathic licensing into the Medical Board was not verified. The 'more than four days' trigger is broad enough to reach ordinary testosterone prescriptions for APRNs and DOs.

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

A vendor summary reports that New Mexico physicians may dispense non-controlled legend drugs to their patients under the medical license with no added registration, and may dispense controlled substances after obtaining a facility controlled substance registration from the Board of Pharmacy (reported fee $60 per year). Dispensing controlled substances above 12 dosage units or a 72-hour supply triggers PMP reporting.

Rule text not reviewed; confirm with the New Mexico Board of Pharmacy.

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

(1) The Medical Board issues a telemedicine license - a limited license allowing a physician located outside New Mexico to practice on patients in New Mexico - to applicants with a full unrestricted license in another state, using the expedited-license documentation (NMSA 1978 61-6-11.1; 16.10.2.8(C) and 16.10.2.11 NMAC); consultants to New Mexico physicians on no more than ten patients a year are exempt. (2) Prescribing without an established physician-patient relationship is unprofessional conduct, but treatment during a face-to-face telehealth encounter using standard videoconferencing, with history, informed consent and a record, and a physical exam either recorded by an on-site practitioner or waived when it would not normally be part of the visit, is allowed (16.10.8.8 NMAC). (3) No New Mexico-specific telehealth limit on controlled substances such as testosterone was found; federal rules apply. (4) IMLC: passed, not yet implemented (implementation in process as of 1/22/2026).

Telemedicine license rules re-promulgated 7/7/2023 (16.10.2 amended 3/12/2024). The telehealth exception in 16.10.8.8 was last amended 2009 but is the current rule text. NMSA 61-6-11.1 (license term up to three years) read via CCHP. New Mexico enacted the IMLC (SB 67); the IMLC map shows implementation in process.

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

Medical Board rule 16.10.13.9 NMAC states that injecting cosmetic or aesthetic substances is the practice of medicine and shall not be delegated to medical assistants. For RNs, Board of Nursing rule 16.12.2.11.H NMAC says RNs may perform functions beyond basic nursing preparation only if they emanate from nursing's body of knowledge, and that emerging functions that do not require national certification from a recognized body; certificates of course completion are not evidence of competency. The Board's 'Aesthetic Certifications' page lists national aesthetic certifications (e.g. CANS) for RNs and APRNs under this rule.

The BON page says its certification information was accessed 2024-04-30. Whether the Board treats neuromodulator/filler injection as an 'emerging function' requiring certification is implied by the page, not stated as a rule; confirm with NMBON. Rule 16.10.13 last amended 2008 (file dated 2021-08-24).

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

The New Mexico Board of Nursing and Medical Board sites (checked 2026-09-23) did not show guidance on IV hydration businesses, individual exams, standing orders or mobile IV services.

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

Permit Health's 2025 guide lists New Mexico as 'Permitted (with conditions)', citing N.M. Stat. §61-6-16 and a 1987 Attorney General opinion; MedPath Compliance (reviewed 2026-06-20) lists New Mexico as 'No' and reports HB 586 (signed 2025-04-07, effective 2025-07-01) requiring approval of certain hospital transactions.

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

Under 16.10.13.8 NMAC, use of cosmetic devices using waveform energy (lasers, IPL) or microwave energy is the practice of medicine. Medical assistants may use only non-incisive, non-ablative devices, must be trained and certified on each device, and may operate only when the supervising physician is immediately available on the premises. Before an assistant treats, the physician must take the history, examine, diagnose, set a written treatment protocol and prepare the record, and must file a device-specific certificate of training with the Board. Advertising must name the responsible physician. RNs and PAs are not 'medical assistants' under this rule and practise under their own licences.

Rule last amended 2008 (possibly stale) but still posted by the Board.

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

Most states rely on federal CLIA certification alone. The states confirmed in this research as issuing their own lab licenses are California, New York, Pennsylvania, Maryland and Rhode Island (which also reach out-of-state labs testing specimens from their residents), plus Nevada, Washington, Massachusetts, New Jersey and New Hampshire (labs located in the state). New Mexico was not among them, but this research did not confirm its statutes. New Mexico's CLIA state agency is New Mexico Health Facility Licensing & Certification (CLIA.DHI@hca.nm.gov, 505-222-8646); it can confirm whether any state license or permit applies, including to out-of-state labs.

Absence of a state license was not verified against the state's statutes or rules.

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

ADLM (formerly AACC) reported in 2019 that 37 states and DC let consumers order some or all tests directly, but it did not publish the state list, and this research did not confirm New Mexico's rule. New Mexico's lab regulator (CLIA state agency) is New Mexico Health Facility Licensing & Certification (CLIA.DHI@hca.nm.gov, 505-222-8646). The question matters for take-home and consumer test kits, not for panels a clinician orders.

The ADLM figure dates from 2019 (older than 2 years).

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

Compilations of state stem-cell laws from 2024 to 2026 list about a dozen states with specific laws (California, Florida, Georgia, Mississippi, Nevada, North Carolina, Tennessee, Texas, Utah, Vermont, Washington and Wyoming), plus Montana's general experimental-treatment law and Kansas's state stem cell center. New Mexico is not among them. Without a state-specific law, regenerative products are governed by federal FDA rules plus the state's general medical practice, advertising and consumer-protection laws, enforced by its medical board. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

The finding of no law rests on multi-state compilations (a commercial one from Aug 2026 and a peer-reviewed one from Feb 2024, which is older than 2 years) and targeted searches, not a statute-by-statute review, and neither compilation is exhaustive. General Right to Try laws for terminal patients, where they exist, were not reviewed here.

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

HB 212 (Chapter 102, signed April 8, 2025) phases in PFAS product bans. Compilations report that cosmetics with intentionally added PFAS may not be sold from Jan 1, 2028, and that from Jan 1, 2032 all products with intentionally added PFAS are banned unless the Environmental Improvement Board designates the use 'currently unavoidable'.

Enactment was confirmed on the Legislature's site; the product dates come from secondary compilations. Federal MoCRA and FDA cosmetic and OTC sunscreen rules apply in every state.